MedTrace Logo

Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

NCT04349592 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2021-02-23

No results posted yet for this study

Summary

Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.

Conditions

  • Covid19

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days

DRUG

Azithromycin

Azithromycin 250 mg capsules oral, 2 capsules on day one, followed by 1 capsule once a day for days 2-5.

OTHER

Placebo Tablet

Oral, one tablet three times a day for 7 days

OTHER

Placebo capsules

Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.

Sponsors & Collaborators

  • Hamad Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Tim R Harris · Hamad Medical Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-14
Primary Completion
2020-08-14
Completion
2020-08-30

Countries

  • Qatar

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04349592 on ClinicalTrials.gov